Tóm tắt
Bệnh nhân cấy máy tạo nhịp khi đang dùng thuốc chống đông. Dừng thuốc chống đông, chuyển thuốc khác hay tiếp tục dùng thuốc?
Trang chủ
CA LÂM SÀNG
Số phát hành:
Bệnh nhân cấy máy tạo nhịp khi đang dùng thuốc chống đông. Dừng thuốc chống đông, chuyển thuốc khác hay tiếp tục dùng thuốc?
Phạm Như Hùng: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Đặng Thị Thanh Hương: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Xuất bản: tháng 4 1, 2015
Views: 2
Tài liệu tham khảo
1.
1. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter- defibrillators: calendar year 2009: a World Society of Arrhythmia’s project. Pacing Clin Electrophysiol. 2011, 34:1013–1027.
2.
2. Phạm Như Hùng, Trần Song Giang, Trần Văn Đồng. Thực trạng cấy máy tạo nhịp 1 buồng và 2 buồng tim trong chỉ định điều trị nhịp chậm tại Viện Tim mạch Việt Nam. Tạp trí tim mạch học số 65 năm 2014 trang 64-69.
3.
3. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J. The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:299S–339S.
4.
4. Tischenko A, Gula LJ, Yee R, Klein GJ, Skanes AC, Krahn AD. Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with lowmolecular weight heparin. Am Heart J. 2009;158:252–256.
5.
5. Robinson M, Healey JS, Eikelboom J, Schulman S et al.. Postoperative low-molecularweight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. Pacing Clin Electrophysiol. 2009;32:378–382.
6.
6. Uslan DZ, Gleva MJ, Warren DK, Mela T, et al. Cardiovascular implantable electronic device replacement infections and prevention: results from the REPLACE Registry. Pacing Clin Electrophysiol. 2012;35:81–87.
7.
7. de Bono J, Nazir S, Ruparelia N, Bashir, Betts T, Rajappan K. Perioperative management of anticoagulation during device implantation-the UK perspective. Pacing Clin Electrophysiol. 2010;33:389–393.
8.
8. Krahn AD, Healey JS, Simpson CS, Essebag V, Sivakumaran S, Birnie DH. Anticoagulation of patients on chronic warfarin undergoing arrhythmia device surgery: wide variability of perioperative bridging in Canada. Heart Rhythm. 2009;6:1276–1279.
9.
9. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Coutu B, Leiria TL, Essebag V; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368:2084–2093.
10.
10. Ghanbari H, Phard WS, Al-Ameri H, et al.. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices. Am J Cardiol. 2012;110:1482–1488.
11.
11. Przybylski A, Derejko P, Kwasniewski W, Urban´czyk-Swic´ D, Zakrzewska J, Orszulak W et al. Bleeding
12.
complications after pacemaker or cardioverterdefibrillator implantation in patients receiving dual antiplatelet therapy: results of a prospective, two-centre registry. Neth Heart J 2010;18:230–5.
13.
12. Dreger H, Grohmann A, Bondke H, Gast B, Baumann G, Melzer C. Is antiarrhythmia device implantation safe under dual antiplatelet therapy? Pacing Clin Electrophysiol 2010;33:394–9.
14.
13. Cano O, Osca J, Sancho-Tello MJ, Olaguăe J, Castro JE, Salvador A. Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices. Europace 2011;13:395–401.
15.
14. Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol 2010;3: 312–8.
16.
15. Wiegand UK, LeJeune D, Boguschewski F, Bonnemeier H, Eberhardt F, Schunkert H et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 2004;126:1177–86.
17.
16. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE et al. Dual antiplatelet therapy and heparin ‘bridging’ significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 2010;55:2376–82.
18.
17. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009; 119:1634–42.
19.
18. Abualsaud AO, Eisenberg MJ. Perioperative management of patients with drug-eluting stents. JACC Cardiovasc Interv 2010;3:131–42.
20.
19. Anne Rose,Ann McBridePatrick Pfau; Melissa Heim; Erin Robinson; Nikki Lokker. Periprocedural Anticoagulation – Adult – Inpatient and Ambulatory– Clinical Practice Guideline 2013.
21.
20. HealeyJS,EikelboomJ,DouketisJ,etal;RE-LYInvestigators.Periproceduralbleedingand thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126:343–348.
22.
21. Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once- Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2013;61:651–658.
23.
22. Rowley CP, Bernard ML, Brabham et al. Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol. 2013;111:1165–1168.
24.
\23. Jennings JM, Robichaux R, McElderry HT, et al Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin. J Cardiovasc Electrophysiol. 2013;24:1125–1129.
25.
Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34:2094–2106.
26.
25. Gallego P, Apostolakis S, Lip GY. Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation. 2012;126:1573–1576.
27.
26. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119:3016–3023.